Disclosures for "Interactions of Fcγ Receptors with an IgG4 Format, Anti-FcRn Monoclonal Antibody, Rozanolixizumab"
-
Dr. Qureshi has received personal compensation for serving as an employee of Celentyx Ltd. Dr. Qureshi has received personal compensation for serving as an employee of UCB Pharma. Dr. Qureshi has stock in Celentyx.
-
Dr. Bithell has nothing to disclose.
-
Miss Cutler has received personal compensation for serving as an employee of UCB.
-
Ms. McCluskey has received personal compensation for serving as an employee of AstraZeneca.
-
Dr. Craggs has received personal compensation for serving as an employee of Dark Blue Therapeutics Ltd. Dr. Craggs has received personal compensation for serving as an employee of e-therapeutics plc.
-
Prof. Barnes has received personal compensation for serving as an employee of Celentyx Ltd. Prof. Barnes has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers. Prof. Barnes has stock in Celentyx Ltd. The institution of Prof. Barnes has received research support from MRC.
-
Dr. Humphreys has received personal compensation for serving as an employee of UCB Pharma. Dr. Humphreys has stock in UCB Pharma.
-
Dr. Rapecki has stock in UCB.
-
Dr. Smith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Smith has stock in UCB.
-
Anthony Shock has received personal compensation for serving as an employee of UCB Pharma.